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Abstract
Background: Adiponectin (APN) is a key player in energy homeostasis strictly associated with cerebrovascular and
neurodegenerative diseases. Since APN also belongs to anti-inflammatory-acting adipokines and may influence
both neuroinflammation and neurodegenerative processes, we decided to study the APN levels in amyotrophic
lateral sclerosis (ALS) and other neurodegenerative diseases.
Methods: We assessed APN levels by ELISA immunoassay in both the serum and cerebrospinal fluid of a cohort of
familial and sporadic ALS patients, characterized by normal body mass index and absence of dysautonomic
symptoms. The screening of serum APN levels was also performed in patients affected by other neurological
disorders, including fronto-temporal dementia (FTD) patients. Means were compared using the non-parametric
Wilcoxon test, and Pearson’s or Spearman’s rho was used to assess correlations between variables.
Results: In the whole ALS group, serum APN levels were not different when compared to the age- and sex-
matched control group (CTR), but a gender-specific analysis enlightened a significant opposite APN trend between
ALS males, characterized by lower values (ALS 9.8 ± 5.2 vs. CTR 15 ± 9.7 μg/ml), and ALS females, showing higher
amounts (ALS 26.5 ± 11.6 vs. CTR 14.6 ± 5.2 μg/ml). This sex-linked difference was significantly enhanced in familial
ALS cases (p ≤ 0.01). The APN levels in ALS cerebrospinal fluids were unrelated to serum values and not linked to
sex and/or familiarity of the disease. Finally, the screening of serum APN levels in patients affected by other
neurological disorders revealed the highest serum values in FTD patients.
Conclusions: Opposite serum APN levels are gender-related in ALS and altered in several neurological disorders,
with the highest values in FTD, which shares with ALS several overlapping and neuropathological features. Further
investigations are needed to clarify the possible involvement of APN in neuroinflammation and neurodegeneration.
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Background
Metabolic dysfunctions characterize neurodegenerative
disorders, such as Alzheimer’s disease (AD) and
Parkinson’s disease (PD), wherein early abnormal lipo-
genesis in glial cells appears a possible mediator of neur-
onal degeneration [1]. Several studies on the involved
biological pathways indicate an active role of signalling
molecules secreted by adipose cells, named “adipokines”.
Adipokines act as hormones modulating a wide range of
physiological metabolic responses from hunger/satiety
and energy balance to inflammation, cardiovascular
function and reproduction, thus connecting adipocytes
to all tissues [2]. Adiponectin (APN) is the most abun-
dant adipokine in the body and is a key player in the sig-
nalling network of adipose tissue. Different biological
cascades (i.e. neurogenesis, inflammatory response, en-
ergy balance of skeletal muscle) as well as pathological
conditions (i.e. diabetes, hypertension, atherosclerosis
and stroke) [3, 4] involve APN action/activation. Accu-
mulating evidence suggests that APN-mediated modula-
tion of macrophage function and phenotype contributes
to its role in controlling inflammation. Adiponectin in-
hibits the transformation of macrophages into foam
cells, reduces intracellular cholesteryl ester content in
human macrophages by suppressing the expression of
class A scavenger receptors and can bind to apoptotic
cells and facilitate their uptake by macrophages. Further-
more, APN levels are increased, rather than decreased,
in a number of chronic inflammatory and autoimmune
diseases [5]. An emerging close association between neu-
rodegenerative diseases and metabolic dysfunctions is
suggested by recent literature, linking APN to the cen-
tral nervous system (CNS) [2]. Subjects suffering from
neurodegenerative disorders, such as AD, PD, multiple
sclerosis and Huntington’s disease, display altered serum
APN levels [2, 3, 6]. Increased levels of APN may be
viewed as a rescue mechanism to counteract the ongoing
neuronal loss, even if dual and opposite effects of APN
on neuroinflammation, oxidative stress and neuronal
apoptosis have been reported [2, 3, 7–11]. Hence, in this
controversial scenario, the APN impact on different
neurological conditions remains undefined, as well as
the eventual ability of APN subforms to cross the blood-
brain barrier (BBB) [3]. Nevertheless, exogenous brain
APN increase is able to directly influence microglia as
well as brain macrophage phenotype and activation
state, thus reducing neuroinflammation and depressive-
like behaviours in mice [8]. Interestingly, higher serum
APN values have been associated with neuroimaging
markers of neurodegeneration and cognitive impairment
among women in the Mayo Clinic Study of Aging [6].
Amyotrophic lateral sclerosis (ALS) is a fatal adult
motor neuron disorder characterized by a progressive
motor neuron loss. Recent evidence indicate that ALS is
a multifactorial disorder rather than a pure neuromuscu-
lar disease [12] and several biological processes are
involved in its pathogenesis [13], such as protein aggre-
gation, glutamate excitotoxicity and neuroinflammation
[14]. The chief mediators of neuroinflammation in ALS
are microglial cells along with other participants
(astrocytes, oligodendrocytes, T lymphocytes) [15].
Neuroinflammation and neurodegeneration are shared
among AD, PD, cerebrovascular disease and ALS,
wherein neuroinflammation shifts from a neuroprotec-
tive anti-inflammatory role, characterizing early patho-
logical stages, to a diffuse neurotoxic pro-inflammatory
state, typical of late phases [15]. The dual action of neu-
roinflammation along ALS onset and progression may
be related to the selective modulation of pro- and anti-
inflammatory cytokines, including some adipokines,
well-known modulators of energy balance [16]. Interest-
ingly, energy metabolism is impaired in both sporadic
(sALS) and familiar ALS (fALS) patients [12, 17].
Hypermetabolism, weight loss, hyperlipidaemia and
impaired glucose tolerance have been reported in ALS
[17], although they are apparently related to advanced
disease severity [18]. In fact, inclusions of TDP-43
(43-kDa trans-activation-responsive region DNA-
binding protein) characterize most of ALS brain
tissues whereas the naïve protein regulates fat depos-
ition and glucose pathway [12, 19]. At diagnosis, pa-
tients usually have a normal or low body mass index
(BMI) and body fat amount seems to be inversely re-
lated to ALS risk [12]. However, with disease progres-
sion, patients usually reduce food intake, partially due
to dysphagia progression, with a consequent weight loss,
muscle mass reduction and paradoxically increased energy
expenditure [12, 17, 20, 21].
Adipose tissue distribution differs between controls
and ALS patients wherein a positive correlation has
been reported between the metabolic state/body fat
percentage and ALS duration/augmented risk of
complications [12]. Latest evidence indicate that sub-
cutaneous fat is predictive of better survival in a
gender-related manner [12]; besides, increasing body
fat may be associated with a decreased risk to develop
ALS and to a longer survival [17].
At present, APN modulation and involvement in neu-
roinflammation and neurodegeneration are poorly inves-
tigated in ALS patients. Interestingly, ALS and one of
the less common forms of dementia, fronto-temporal
dementia (FTD), share common neurological features
together with distinct changes in metabolism, as recently
reported [13, 22, 23].
The purposes of our study were to assess (1) serum
and cerebrospinal fluid (CSF) APN levels in both fALS
and sALS patients in comparison to age- and sex-
matched normal weight healthy controls, exploring any
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possible correlation to clinical parameters, and (2) serum




This study was conducted in accordance with the Dec-
laration of Helsinki. The research protocol was approved
by the ethics committee of IRCCS Istituto Auxologico
Italiano, and written informed consent was obtained
from all participants.
ALS patients and controls
A total of 88 serum samples were collected: 36 from
healthy lean controls (CTR), genetically unrelated to the
patients, not suffering from any known disease condi-
tions and specifically not affected by neurological dis-
eases, and not underweight (BMI ≤18.5 kg/m2). Controls
were compared to 52 clinically diagnosed ALS patients,
matched for age, sex and BMI (see details in Tables 1
and 2). All our patients possess normal BMI. The fALS
group included patients carrying mutations in SOD1 (2
males and 3 females), C9ORF72 (1 male and 3 females)
and TARDBP (1 male) genes. ALS patients fulfilled both
criteria defined by the revised El Escorial criteria
(categories: laboratory-supported probable, probable and
definite [24, 25]), with the exclusion of patients affected
by possible ALS, and the Awaji criteria (categories:
probable and definite [26]). Dementia was diagnosed
in 4 female ALS patients [27]. Both patients with spinal
and bulbar onset and without swallowing impairment
or metabolic alterations at the time of sample collec-
tion were enrolled. Analyses of CSF were restricted
only to ALS patients (23 samples) due to ethical con-
cerns (additional details in Tables 1 and 2). Addition-
ally, 3 FTD CSFs were analysed since available for
clinical reasons. All patients were treated with the
standard drug for ALS (riluzole, 100 mg daily). Weight
and height were measured and BMI (kg/m2) calculated for
all patients.
Obese patients (technical controls)
Few obese subjects (8: 6 females and 2 males) were used
as technical controls since serum APN levels are de-
creased in individuals with visceral obesity [28].
Other neurological diseases
Forty-seven subjects with different neurological disor-
ders were enrolled (see details in Table 3): 7 FTD, 21
dysimmuno-neuropathy (DN) and 9 AD patients.
Additionally, 10 patients with neither the cited neuro-
degenerative nor inflammatory but other neurological
diseases (OND, such as corticobasal degeneration,
polyneuropathy, stroke) were included. Duration of
symptoms and the primary diagnosis for each disease
were based on the corresponding diagnostic criteria
[29–31]. Exclusion criteria included patients who did
not give consent as well as those affected by meta-
bolic diseases (i.e. metabolic syndrome), glucose in-
tolerance and/or known diabetes.
Table 1 Characteristics of patients with ALS and control subjects (CTR) in the whole cohort and divided by gender
Whole cohort Females Males
CTR ALS CTR ALS CTR ALS
No. of serum samples 36 52 17 27 19 25
No. of CSF samples 23 12 11
Age (years) 52.8 ± 17.8 57.9 ± 14.1 49.6 ± 19.1 59.1 ± 14.2 55.7 ± 16.6 56.6 ± 14.2
BMI (kg/m2) 22.5 ± 2.5 23.6 ± 3.4 22.6 ± 2.5 23.3 ± 2.6 22.4 ± 2.6 23.8 ± 3.8
Fasting glucose (mg/dl) 88.1 ± 10.9 90.9 ± 13.8 85.5 ± 19.1 87.9 ± 12.8 90.2 ± 12.6 93.5 ± 14.4
Total cholesterol (mg/dl) 192.2 ± 25.5 210 ± 44.6 185.4 ± 23 219.3 ± 42.3b 199.7 ± 27 201 ± 45.8
HDL (mg/dl) 56.9 ± 17.8 60.4 ± 17.4 60.7 ± 22 69.8 ± 15 53.8 ± 13.2 51.3 ± 14.5c
LDL (mg/dl) 117.2 ± 39 137.1 ± 37 107.2 ± 23.3 134.9 ± 37.8 127.2 ± 49.6 138.9 ± 37.4
Triglycerides (mg/dl) 94.2 ± 25.3 103.1 ± 29.6 92.0 ± 31.1 97.9 ± 25.8 96.1 ± 19.5 108.1 ± 32.6
GOT (AST) (U/l) 18.2 ± 5.6 25.6 ± 10.6a 17.5 ± 6.2 22.5 ± 8.3 18.9 ± 5.3b 28.5 ± 11.9c,d
GPT (ALT) (U/l) 18.2 ± 9.3 29.90 ± 16.89a 16.6 ± 6.1 24.3 ± 15.5 19.6 ± 11.5b 33.1 ± 16.4c,d
GTP (γ-GT) (U/l) 17 ± 6.5 25.8 ± 21.3 15.2 ± 5.9 18.4 ± 14.6 18.8 ± 6.8 33.6 ± 24.6 c,d
White blood cells (n) 6.9 ± 2.2 6.7 ± 1.7 6.8 ± 1.8 6.3 ± 1.7 7 ± 2.6 7 ± 1.7
Lymphocytes (n) 28.9 ± 9.2 28.7 ± 9.8 29.1 ± 11.9 29.5 ± 11.9 28.7 ± 6.4 28.1 ± 7.7
BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, GOT (AST) glutamic oxaloacetic transaminase/aspartate aminotransferase,
GPT (ALT) glutamate-pyruvate transaminase 1/alanine aminotransferase, GTP (γ-GT) gamma-glutamyl transpeptidase
p < 0.05: avs. CTR; bvs. CTR F; cvs. ALS F; dvs. CTR M
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Collection of biological specimens
Blood samples
Two venous blood samples were collected the morn-
ing after an overnight fasting from each subject. After
blood clot at room temperature, the samples were im-
mediately centrifuged at 2000×g for 15 min at +4 °C
to obtain serum, aliquoted in vials and stored at
−80 °C until use. On the day of analysis, the samples
were brought to room temperature and vortexed be-
fore analysis.
CSF samples
0.5 ml of CSF was collected, under sterile conditions by
spinal tap (lumbar puncture), immediately aliquoted,
frozen and conserved at −80 °C until use. Blood-
contaminated CSFs were excluded from the analysis.
Sample analysis
APN detection
Human APN total levels (all subforms) were measured
using a commercially available enzyme-linked immuno-
sorbent assay kit (EIA-4177 DRG® Adiponectin Human
ELISA, Springfield, NJ, USA), following the manufac-
turer’s instructions. Although peripherally the high mo-
lecular weight APN is considered the most biologically
active, we preferred to evaluate total APN values in both
the serum and CNS in order to detect any eventual al-
teration, as reported in other studies [6]. Sera were di-
luted 1:500 whereas CSF samples were undiluted. The
absorbance measurement at 450 nm was performed
using a microplate absorbance reader (Sunrise, Tecan,
Männedorf, Switzerland) and data analysed with the pro-
vided Magellan™ Data Analysis software.
Blood analysis
Standard complete blood screenings were conducted for
each patient at the diagnostic unit of our institute certi-
fied by the Italian Ministry of Health (see details in
Tables 1, 2 and 3).
Statistics
The statistical analysis of data was carried out using JMP
software, version 3.2.6, SAS Institute Inc, Cary, NC,
USA. Means were compared using the non-parametric
Wilcoxon test. Pearson’s or Spearman’s rho was used
Table 3 Characteristics of patients with neurological diseases
CTR ALS FTD DN AD OND
N 36 52 7 21 9 10
F/M 17/19 27/25 2/5 14/7 4/5 4/6
Age (years) 52.8 ± 17.8 57.9 ± 14.10c 73 ± 4.2a 50.8 ± 16.8c,d 69.9 ± 7.8a,b 59.7 ± 20.4
BMI (Kg/m2) 22.5 ± 2.5 23.6 ± 3.4e 23.2 ± 2.3 22.8 ± 2.5 24.5 ± 3.7 25.3 ± 4.3a
Fasting Glucose (mg/dl) 88.1 ± 10.9 90.9 ± 13.8 92.3 ± 12.9 107.1 ± 41.3 99.7 ± 19.6 101.8 ± 17.8
Total Cholesterol (mg/dl) 192.2 ± 25.5 210 ± 44.6 182.2 ± 39.9 217.1 ± 41.4a 189.8 ± 32.4 202.5 ± 43.8
HDL (mg/dl) 56.9 ± 17.8 60.4 ± 17.4 49.7 ± 16.5 62.8 ± 16 59.2 ± 15.3 57.8 ± 15.7
LDL (mg/dl) 117.2 ± 39 137.1 ± 37 121 ± 29.1 134.9 ± 41.7 114.4 ± 28 143.6 ± 43
Triglycerides (mg/dl) 94.2 ± 25.3 103.1 ± 29.6 109.5 ± 51.5 111.5 ± 54.9 89.7 ± 30.1 95.4 ± 33.9
GOT (U/L) 18.2 ± 5.6 25.6 ± 10.6a 22.5 ± 11.6 18.2 ± 4.8b 20.4 ± 4.6 19.6 ± 8.3
GPT (U/L) 18.2 ± 9.3 29.90 ± 16.89a 15.7 ± 5b 19.6 ± 8.3b 19.9 ± 6.2 26.5 ± 18.9
GTP (U/L) 17 ± 6.5 25.8 ± 21.3 16.7 ± 6.7 22.9 ± 11.7 26.1 ± 22.9 34.5 ± 22.6a
White Blood Cells (n) 6.9 ± 2.2 6.7 ± 1.7e 7.5 ± 1.9 7.3 ± 2.3 6.8 ± 1.8 8.6 ± 2a
Lymphocytes (n) 28.9 ± 9.2 28.7 ± 9.8 26.6 ± 6.8 28.3 ± 12.3 30.1 ± 8.7 29.2 ± 9.7
F females, M males, BMI Body Mass Index, HDL High density lipoprotein cholesterol, LDL Low-density lipoprotein cholesterol, GOT (AST) Glutamic Oxaloacetic
Transaminase/Aspartate aminotransferase, GPT (ALT) Glutamate-Pyruvate Transaminase 1/Alanine aminotransferase, GTP (γGT) Gamma-glutamyl TransPeptidase
p < 0.05 a vs. CTR; b vs. ALS; c vs. FTD; d vs. AD; e vs. OND
Table 2 Characteristics of ALS patients divided by gender
ALS F (27) ALS M (25)
Hypertension (Y/N) 7/20 6/19
Dementia (Y/N) 4/23 0/25
ALS-FRS-R score 38.6 ± 6.9 38.4 ± 8.7
Disease duration (months) 25.5 ± 23.2 29.1 ± 32.1
I MN involvement (Y/N) 26/1 22/3
II MN involvement (Y/N) 27/0 25/0
Onset (bulbar/spinal) 7/20 3/22
Bulbar involvement (Y/N) 18/9 10/15
sALS/fALS sera 21 (40.4%)/6 (11.5%) 21 (40.4%)/4 (7.7%)
sALS/fALS CSF 7 (30.4%)/5 (21.8%) 9 (39.1%)/2 (8.7%)
F females, M males, MN motor neuron, sALS sporadic ALS, fALS familiar ALS
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to assess correlations between two variables at a time.
A p value of 0.05 was the set limit for statistical significance.
All the opportune statistical corrections were applied when-
ever necessary in order to detect unbiased differences
among groups.
Results
Characteristics of ALS patients vs. CTR
The whole group of ALS patients was comparable to
CTR for all the considered parameters, except for glu-
tamic oxaloacetic transaminase/aspartate aminotransfer-
ase (GOT (AST)) and glutamate-pyruvate transaminase
1/alanine aminotransferase (GPT (ALT)) levels, which
were significantly increased (p < 0.05, Table 1). The com-
parison between ALS and CTR by gender revealed
significant variations (Table 1). ALS males were charac-
terized by significantly different values for ALT and AST
in comparison to CTR, as for the whole group, whereas
in female ALS, only total cholesterol levels were slightly
increased. Comparison between ALS females vs. males
enlightened significantly higher values in males for en-
zyme markers of liver disease (GOT (AST) p ≤ 0.035;
GPT (ALT) p ≤ 0.014; GTP (γ-GT) p ≤ 0.038). High-
density lipoprotein (HDL) was significantly higher only
in female ALS, as expected (Table 1).
Although the reported mean disease duration for ALS
patients is 25.5 ± 23.2 and 29.1 ± 32.1 months for females
and males, respectively (Table 2), the higher values
observed for disease duration were mainly due to 3
patients characterized by very slow progression
(≥100 months, ≥8 years) jointed to preservation of nor-
mal BMI. Hypertension was observed in 25% of ALS pa-
tients. No statistically significant differences for ALS
Functional Rating Scale-Revised (ALS-FRS-R, see details
at https://www.encals.eu/wp-content/uploads/2016/09/
ENCALS-SOP-for-ALSFRS-R-v1.2.pdf ) and disease dur-
ation were observed in ALS patients by sex (Table 2).
No statistically different values were observed for blood
screenings between fALS and sALS patients (not
shown). Finally, almost all ALS female patients were in
menopause status.
APN detection in ALS vs. CTR samples
We confirmed lower serum APN mean values in OB
subjects in respect to CTR (used as technical controls,
not shown) [3, 28]. In the whole ALS patient group,
serum APN levels were similar when compared to all
CTR (18.5 ± 12.3 vs. 14.8 ± 7.8 μg/ml, p = 0.33, ns).
Nevertheless, gender analysis of serum APN revealed a
significant increase only in ALS female patients in re-
spect to both female and male CTR as well as to ALS
males (Fig. 1a). Circulating APN levels were higher in
ALS females (26.51 ± 11.6 μg/ml) and lower in ALS
males (9.8 ± 5.2 μg/ml) than the corresponding CTR
(Fig. 1a) whereas comparable amounts were retrieved in
CSF (Fig. 1b) between ALS males and females (respect-
ively, 10.43 ± 5.2 vs. 13.5 ± 11.1 ng/ml, p = 0.7, ns). Al-
though our ALS cohort comprised 4 females diagnosed
with dementia, their exclusion maintained a statistical
significance for APN values (p ≤ 0.0001, not shown).
No significant APN levels were observed in the CSF of
ALS patients by sex (Fig. 1b). Serum APN levels were
significantly different when bulbar involvement and gen-
der were considered (see Fig. 1c).
No differential APN levels were retrieved in both
serum and CSF, irrespectively of any eventual genetic
mutation present in all ALS patients (Fig. 2a). However,
the APN levels were significantly higher in female fALS
compared to sALS, whereas significant lower levels were
observed in fALS males (Fig. 2b). Gender analysis of
APN levels in CSF revealed no significant differences be-
tween sALS and fALS (Fig. 2c).
Association with clinical measures
Correlation studies between mean serum APN values
and clinical parameters of ALS patients enlightened a
positive association with HDL (Fig. 3). The significant
HDL association with APN was maintained after gen-
der correction (males: rho = 0.56, p = 0.003; females:
rho = 0.53, p = 0.01, not shown). No significant corre-
lations were retrieved for CSF APN levels.
Fig. 1 Gender serum APN levels (μg/ml) in the comparison between
ALS and CTR (a) and CSF APN levels (ng/ml) in ALS patients (b).
Differences in serum APN between ALS subgroups by gender and
bulbar involvement (c). Mean ± SE is reported. *p < 0.05,
**p < 0.01, ***p < 0.001
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Interestingly, HDL and total cholesterol had an inverse
correlation with ALS-FRS-R scores (p ≤ 0.01, not shown).
Serum APN values in ALS patients analysed by sex
showed no significant differences for type of onset, upper
or lower motor neuron involvement and disease duration.
No associations between bulbar impairment, hypertension
or onset and serum APN levels were retrieved.
Only in female ALS, serum APN values had an in-
verse correlation with ALS-FRS-R scores (rho = 0.24,
p ≤ 0.004). CSF APN in ALS females was inversely related
to the cell number of basophils (rho = −0.63, p = 0.011)
and monocytes (rho = −0.83, p = 0.001). In ALS males, a
direct correlation between ALS-FRS-R scores and BMI
(rho = 0.48, p = 0.04) was found, and we confirmed an in-
verse one for HDL (rho = −0.53, p = 0.01) and total choles-
terol (rho = −0.49, p = 0.03, not shown) levels.
APN detection in other neurological diseases
Alterations of serum APN observed in ALS patients
prompted us to check this adipokine in other neurological
Fig. 2 Whole group serum and CSF APN levels in sALS vs. fALS patients (a). Comparison of serum (b) and CSF (c) APN levels in sALS vs. fALS
patients stratified by gender. Mean ± SE is reported. *p < 0.05, **p < 0.01, ***p < 0.001
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diseases (AD, DN, OND and FTD, which share involve-
ment of the frontal cortex as ALS) in search of specific or
common hallmarks within these pathologies.
The clinical characteristics of the studied cohort are
detailed in Table 3. No significant differences in the en-
rolled subjects for BMI were observed since all patients
were in the BMI normal range (between 20 and 25 kg/
m2). The whole ALS cohort was significantly younger
than FTD patients (p ≤ 0.032) whereas FTD (p ≤ 0.014)
and AD (p ≤ 0.011) patients were significantly older than
CTR (Table 3). Significant differences for age were
present between DN and FTD (p ≤ 0.030) (see Table 3).
The overall analysis of APN levels enlightened that
serum APN was significantly increased in AD and FTD
patients when compared to CTR (see Fig. 4). Surpris-
ingly, FTD patients displayed the highest serum APN
concentration (31.4 ± 15.2 μg/ml), and albeit the re-
stricted number of FTD patients included, their mean
APN level was significantly higher than those of DN pa-
tients and CTR (Fig. 4). Interestingly, APN levels were
also significantly different between ALS and FTD pa-
tients, although these pathologies share overlapping fea-
tures. A significant difference for serum APN level was
observed between DN and AD patients (Fig. 4).
Due to the small number of CSF collected for OND,
the APN comparison was only restricted to ALS and 3
FTD patients, with a significant difference for high levels
in the latter group (10.3 ± 5.7 vs. 20.4 ± 6.3 ng/ml).
Discussion
We herein demonstrate that serum APN levels
characterize ALS patients with normal BMI in a gender-
specific manner, and this difference is enhanced in fALS,
irrespectively of the genetic mutation carried. The circu-
lating APN amounts also appeared unrelated to CSF
levels in ALS patients. In addition, circulating APN
levels were altered in different neurological diseases,
with the highest levels observed for the very first time in
FTD patients.
Interestingly, similar data showing altered expression
of several metabolic proteins and adipokines has been
previously reported, but only in sALS patients with limb
onset [32]. Conversely, our study was focused on early
pathophysiological ALS stages when neither metabolic
defect- nor systemic inflammatory-altered markers were
evident.
In ALS, altered modulation of the APN signalling
pathway has been linked to muscle atrophy [12] and en-
ergy imbalance has been associated with compromised
mitochondrial biogenesis besides oxidative capacity in
skeletal muscle [4]. Several mechanisms contribute to al-
tered energy balance in ALS from decreased energy sup-
ply and fat storage to increased energy expenditure
(reviewed in [18]), but globally, these features appear to
affect disease progression more than onset [18]. No in-
fluence of riluzole treatment on APN levels has been
previously reported [32]. Moreover, in the present study,
every ALS patient was treated with riluzole, thus exclud-
ing a possible role of this drug on the observed APN
levels.
Serum APN levels normally increase linearly with age-
ing, without any apparent correlation to endogenous sex
hormones [33]. A complex interaction between gender
and clinical phenotypes has been described in ALS with
a higher prevalence of the disease in males, possibly due
to the protective effect of oestrogen [34]. Gender is re-
ported to differentially influence muscle fibres, the site
of onset, the hormonal asset and the pathological
Fig. 3 Scatter plot showing the direct correlation between serum
APN (μg/ml) and HDL values (mg/dl) within the whole ALS cohort.
Number of patients 52, rho = 0.44, ***p < 0.001
Fig. 4 Serum APN levels (μg/ml) in patients affected by different
neurological diseases (ALS amyotrophic lateral sclerosis, FTD fronto-
temporal dementia, DN dysimmuno-neuropathy, AD Alzheimer’s
disease, OND other neurological diseases) when compared to CTR.
Mean ± SE is reported. *p < 0.05, **p < 0.01, ***p < 0.001
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anatomical alterations in ALS [35]. Adiponectin and its
receptor R1 regulate a specific disease modifier, peroxi-
some proliferator-activated receptor gamma coactivator-
1α, which is downregulated in ALS human skeletal
muscles [4, 36] and is able to modulate disease onset as
well as progression in males [37]. The retrieved reduced
APN levels in ALS males may therefore be influenced,
and possibly explained, also by the gender-specific body
fat amount and distribution [38]. Systematic anthropo-
metric studies to determine body composition on a wide
cohort of ALS patients are still lacking and deserve
investigation.
Independently from the genetic background, altered
gender-related APN levels in ALS patients suggest a
pleiotropic change in the adipokine network due to
the disease affecting several body districts. This
anomaly is shared by all ALS patients with normal
BMI, worsened in fALS and directly correlated to bul-
bar involvement. The genetic background of the dis-
ease reinforces the gender effect observed for APN
levels in ALS.
Actually, it is tempting to speculate that gender-
specific alterations of circulating APN cause the same
biological effect through different mechanisms. Female
ALS patients may show a kind of “adiponectin resist-
ance” with desensitized APN receptors, whereas male
ALS patients may be characterized by a kind of
“adiponectin deficiency” (Fig. 5). Therefore, APN dys-
regulation may enhance neuroinflammation and ex-
acerbate motor neuron degeneration in addition to
ageing, metabolic diseases and viral infections [39].
Concordantly, the neuroprotective effect of a plant
APN homolog, osmotin, has already been demon-
strated on the lipopolysaccharide (LPS)-induced re-
lease of inflammatory mediators, thus reducing the
related apoptotic neurodegeneration as well as enhan-
cing synaptic functionality [40].
At the same time, we cannot exclude a gender-
different clearance rate of APN at the liver/kidney level
[41], as already demonstrated in type 2 diabetes patients
wherein APN urinary excretion may be an independent
indicator of vascular damage [42].
Fig. 5 Hypothetical role of gender-specific APN alterations in ALS. Both genders share the same pathological features but opposite serum APN
levels (a, b). Therefore, different biological cascades (c) may induce disruption of APN signalling in ALS patients and enhance neuroinflammation
and motor neuron degeneration (d), so a clear dissection of their single contribution deserves to be deeply investigated
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Interestingly, the direct significant correlation between
APN levels and HDL values suggests that this parameter
may be predictive of APN quantification in ALS patients.
Conversely, APN levels were independent of BMI and
systemic inflammatory status in ALS patients, according
to previous literature [32].
The association between peripheral and CNS levels is
still controversial [3, 43–45], but our data reveal inde-
pendent amounts within these districts. A similar differ-
ence between plasma and CSF was demonstrated for
progranulin protein [46], thus suggesting no main alter-
ations of BBB or, alternatively, a compromised modula-
tion of APN in the ALS CNS. The observed APN levels
in the CSF of ALS patients are in line with literature
data for healthy controls [44].
Adiponectin alterations were observed in all neuro-
logical diseases considered, with FTD patients displaying
the highest amounts. Although FTD and AD patients
were significantly older than the other categories, the ap-
propriate age adjustment maintained the significance,
thus suggesting a reduced effect of ageing. In the studied
cohort of female ALS, APN levels were extremely ele-
vated and not associated with dementia diagnosis. As
already demonstrated in women [47], we cannot exclude
that APN increased levels may prospectively act as a
“prodromic factor” for dementia/cognitive impairment
in ALS. Levels of APN may also be translatable in select-
ive biomarkers for cognitive impairment among two
closely related conditions with overlapping clinical fea-
tures, such as ALS and FTD [13, 22, 23]. However, fur-
ther investigations are required to better explain the
correlation between APN and neuroinflammation.
Conclusions
Our data demonstrate circulating APN alterations in
several neurodegenerative diseases characterized by neu-
roinflammation. We report a gender-related opposite
APN trend in ALS patient sera, but normal levels in
their CSF. In addition, in FTD patients sharing some
overlapping clinical features with ALS, the highest serum
APN levels were observed.
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